COVID-19 DNA Vaccine Halt Another Blow To AnGes

R&D Starts On Intranasal Vaccine

AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.

Following the cancellation of DNA vaccine for COVID-19, Anges will start a new joint research for intranasal alternative
Following the cancellation of a DNA vaccine for COVID-19, Anges will start joint research for an intranasal alternative • Source: Shutterstock

In a setback for the Japanese bioventure, AnGes, Inc. has discontinued a government-supported R&D project for an injected DNA plasmid vaccine for the original Wuhan strain of COVID-19.

While the Osaka-based firm said it was currently difficult to predict the business impact of the cancellation for accounting reasons, the move presents another challenge given its only commercialized product, the gene therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By 

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By 

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By 

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By 

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

More from Focus On Asia